Abstract | OBJECTIVE: METHODS: A prospective nested case-control study was carried out in 114 men who developed CVD and 105 controls. Participants did not use lipid lowering drugs at baseline. Plasma CET was assayed using an isotope method. RESULTS: Plasma CET was 19% higher (P=0.030), whereas CETP mass was unaltered (P=0.30) in cases vs. controls. Plasma CET predicted CVD (age-adjusted hazard ratio (HR): 1.20 (95% CI 1.02-1.46, P=0.028), but incident CVD was unrelated to CETP mass (HR: 0.88 (95% CI 0.73-1.07), P=0.20). Plasma CET still predicted CVD after additional adjustment for total cholesterol/HDL cholesterol, triglycerides and non- lipid risk markers (HR: 1.22 (95% CI 1.02-1.46, P=0.031). CONCLUSION: Plasma CET rather than CETP mass may be a determinant of cardiovascular risk.
|
Authors | Paul J W H Kappelle, Frank Perton, Hans L Hillege, Geesje M Dallinga-Thie, Robin P F Dullaart |
Journal | Atherosclerosis
(Atherosclerosis)
Vol. 217
Issue 1
Pg. 249-52
(Jul 2011)
ISSN: 1879-1484 [Electronic] Ireland |
PMID | 21524747
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Apolipoproteins B
- CETP protein, human
- Cholesterol Ester Transfer Proteins
- Cholesterol Esters
- Lipoproteins, HDL
|
Topics |
- Aged
- Apolipoproteins B
(metabolism)
- Cardiovascular Diseases
(blood, diagnosis)
- Case-Control Studies
- Cholesterol Ester Transfer Proteins
(blood)
- Cholesterol Esters
(blood)
- Gene Expression Regulation
- Humans
- Lipoproteins, HDL
(metabolism)
- Male
- Middle Aged
- Prospective Studies
- Regression Analysis
- Risk
|